BIOCRYST PHARMACEUTICALS, INC. Cost of Revenue
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Cost of Revenue of $3.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $3.84M, a 37.24% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2026-03-31 was $5.38M, a 17.71% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $9.52M, a 56.25% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $2.19M, a 31.89% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2025 was $19.07M, a 55.47% increase from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2024 was $12.27M, a 173.80% increase from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2023 was $4.48M, a 30.07% decline from fiscal 2022.
- BIOCRYST PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2022 was $6.41M, a 11.36% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.84M 10-Q · filed 2026-08-05 | $9.22M 10-Q · filed 2026-08-05 | $18.74M derived: sum of 3 quarters · filed 2026-08-05 | $20.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $5.38M 10-Q · filed 2026-05-06 | $14.90M derived: sum of 2 quarters · filed 2026-05-06 | $17.09M derived: sum of 3 quarters · filed 2026-05-06 | $19.88M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $9.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.71M derived: sum of 2 quarters · filed 2026-02-26 | $14.51M derived: sum of 3 quarters · filed 2026-08-05 | $19.07M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.19M 10-Q · filed 2025-11-04 | $4.99M derived: sum of 2 quarters · filed 2026-08-05 | $9.55M 10-Q · filed 2025-11-04 | $15.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.80M 10-Q · filed 2026-08-05 | $7.37M 10-Q · filed 2026-08-05 | $13.46M derived: sum of 3 quarters · filed 2026-08-05 | $16.67M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $4.57M 10-Q · filed 2026-05-06 | $10.66M derived: sum of 2 quarters · filed 2026-05-06 | $13.87M derived: sum of 3 quarters · filed 2026-05-06 | $15.57M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $6.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.30M derived: sum of 2 quarters · filed 2026-02-26 | $11.00M derived: sum of 3 quarters · filed 2026-02-26 | $12.27M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.21M 10-Q · filed 2025-11-04 | $4.91M derived: sum of 2 quarters · filed 2025-11-04 | $6.17M 10-Q · filed 2025-11-04 | $7.73M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.70M 10-Q · filed 2025-08-05 | $2.96M 10-Q · filed 2025-08-05 | $4.52M derived: sum of 3 quarters · filed 2026-02-26 | $5.62M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.26M 10-Q · filed 2025-05-06 | $2.82M derived: sum of 2 quarters · filed 2026-02-26 | $3.92M derived: sum of 3 quarters · filed 2026-02-26 | $4.82M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.66M derived: sum of 2 quarters · filed 2026-02-26 | $3.55M derived: sum of 3 quarters · filed 2026-02-26 | $4.48M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.10M 10-Q · filed 2024-11-05 | $1.99M derived: sum of 2 quarters · filed 2024-11-05 | $2.92M 10-Q · filed 2024-11-05 | $5.31M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $894.00K 10-Q · filed 2024-08-06 | $1.82M 10-Q · filed 2024-08-06 | $4.21M derived: sum of 3 quarters · filed 2025-02-25 | $7.75M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $931.00K 10-Q · filed 2024-05-07 | $3.31M derived: sum of 2 quarters · filed 2025-02-25 | $6.86M derived: sum of 3 quarters · filed 2025-02-25 | $7.10M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $5.93M derived: sum of 2 quarters · filed 2025-02-25 | $6.17M derived: sum of 3 quarters · filed 2025-02-25 | $6.41M 10-K · filed 2025-02-25 |
| 2022-09-30 | $3.54M 10-Q · filed 2023-11-08 | $3.79M derived: sum of 2 quarters · filed 2023-11-08 | $4.03M 10-Q · filed 2023-11-08 | $4.44M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $246.00K 10-Q · filed 2023-08-07 | $482.00K 10-Q · filed 2023-08-07 | $900.00K derived: sum of 3 quarters · filed 2024-02-27 | $1.49M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $236.00K 10-Q · filed 2023-05-08 | $654.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.25M derived: sum of 3 quarters · filed 2024-02-27 | $1.54M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $418.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.01M derived: sum of 2 quarters · filed 2024-02-27 | $1.31M derived: sum of 3 quarters · filed 2024-02-27 | $7.23M 10-K · filed 2024-02-27 |
| 2021-09-30 | $591.00K 10-Q · filed 2022-11-04 | $888.00K derived: sum of 2 quarters · filed 2022-11-04 | $6.81M 10-Q · filed 2022-11-04 | $6.84M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $297.00K 10-Q · filed 2022-08-05 | $6.22M 10-Q · filed 2022-08-05 | $6.25M derived: sum of 3 quarters · filed 2023-02-27 | $7.77M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $5.92M 10-Q · filed 2022-05-09 | $5.96M derived: sum of 2 quarters · filed 2023-02-27 | $7.47M derived: sum of 3 quarters · filed 2023-02-27 | $7.47M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $1.55M derived: sum of 2 quarters · filed 2023-02-27 | $1.55M derived: sum of 3 quarters · filed 2023-02-27 | $1.55M 10-K · filed 2023-02-27 |
| 2020-09-30 | $1.52M 10-Q · filed 2021-11-04 | $1.52M derived: sum of 2 quarters · filed 2021-11-04 | $1.52M 10-Q · filed 2021-11-04 | $3.84M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | $2.33M derived: sum of 3 quarters · filed 2022-02-28 | $2.33M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-07 | $2.33M derived: sum of 2 quarters · filed 2022-02-28 | $2.33M derived: sum of 3 quarters · filed 2022-02-28 | $2.33M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.33M derived: sum of 2 quarters · filed 2022-02-28 | $2.33M derived: sum of 3 quarters · filed 2022-02-28 | $3.73M 10-K · filed 2022-02-28 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $1.40M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-07 | $1.40M 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $1.40M 10-Q · filed 2020-05-11 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $1.14M derived: sum of 2 quarters · filed 2020-03-13 | $1.14M 10-K · filed 2020-03-13 | |
| 2017-09-30 | $1.14M 10-Q · filed 2018-11-08 | $1.14M 10-Q · filed 2018-11-08 | ||
| 2016-12-31 | $2.30M 10-K · filed 2019-03-14 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | $0.00 derived: sum of 2 quarters · filed 2013-03-11 | $86.00K 10-K · filed 2013-03-11 | |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $86.00K 10-Q · filed 2011-11-03 | ||
| 2010-06-30 | $86.00K 10-Q · filed 2011-08-04 | |||
| 2009-12-31 | $4.54M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |